FACTORS FOR METABOLIC ABNORMALITIES IN CHILDREN WITH PSYCHIATRIC DISORDERS

精神疾病儿童代谢异常的因素

• 批准号: 8167216
• 负责人: CHRISTOPH U CORRELL
• 金额: $ 8.14万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167216
• 关键词: Adolescent; Adverse effects; Adverse event; Antipsychotic Agents; Benign; Biochemical; Biological; Body Composition; Child; Clinical; Computer Retrieval of Information on Scientific Projects Database; Data; Disease; Disruptive Behavior Disorder; Funding; Generations; Glucose; Grant; Health; Imaging Techniques; Institution; Mental disorders; Metabolic; Moods; Pharmaceutical Preparations; Public Health; Reporting; Research; Research Personnel; Resources; Source; United States National Institutes of Health; age group; improved; lipid metabolism; risk benefit ratio

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent reports of second-generation antipsychotic (SGAP)-associated adverse events have challenged the assumption that these agents have a relatively benign side effect profile. Despite the ever more increasing utilization of SGAPs in children and adolescents, there are only very limited data available about their risk benefit ratio in an age group with particular sensitivity to side effects. As children and adolescents with psychotic, mood and aggressive disorders most often will require long-term treatment with psychiatric medications, a better understanding of the side effect burden and of predictors for these is of crucial importance in order to improve compliance and overall health. This study investigates the effects of second-generation antipsychotic medications on body composition and glucose and lipid metabolism in children and adolescents with psychotic, mood and disruptive behavior disorders. Using clinical, biochemical and imaging techniques, this study aims at the identifiction of clinical and biological predictors as well as mechanisms for these side effects with enormous public health importance.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 最近关于第二代抗精神病药物(SGAP)相关不良事件的报道挑战了这些药物具有相对良性副作用的假设。尽管SGAP在儿童和青少年中的使用率越来越高，但在对副作用特别敏感的年龄组中，关于其风险受益率的数据非常有限。由于患有精神病、情绪和攻击性障碍的儿童和青少年通常需要长期接受精神药物治疗，因此更好地了解副作用负担和这些副作用的预测因素对于改善依从性和整体健康至关重要。 本研究调查了第二代抗精神病药物对患有精神病、情绪和破坏性行为障碍的儿童和青少年身体成分和糖脂代谢的影响。这项研究利用临床、生化和成像技术，旨在识别临床和生物学预测因素以及这些具有巨大公共卫生重要性的副作用的机制。